Paysign, Inc. (PAYS)

Theseus Pharmaceuticals Stock Forecast

Stock Price Forecast

The 4 analysts that cover Theseus Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $7.31, which forecasts a 30.30% increase in the stock price over the next year. The lowest target is $5.00 and the highest is $10.

Price Target: $7.31 (+30.30%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$5.00	$7.31	$8.25	$10
Change	-10.87%	+30.30%	+47.06%	+78.25%

Analyst Ratings

The average analyst rating for Theseus Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Mar '25	Apr '25	May '25	Jun '25	Jul '25	Aug '25
Strong Buy	2	2	3	3	3	3
Buy	1	1	1	1	1	1
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	3	3	4	4	4	4

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Jacob Stephan Lake Street	Lake Street	Strong Buy Maintains $9 → $10	Strong Buy	Maintains	$9 → $10	+78.25%	Aug 6, 2025
Jacob Stephan Lake Street	Lake Street	Strong Buy Maintains $7 → $9	Strong Buy	Maintains	$7 → $9	+60.43%	Jun 26, 2025
Peter Heckmann DA Davidson	DA Davidson	Strong Buy Maintains $5 → $6	Strong Buy	Maintains	$5 → $6	+6.95%	May 14, 2025
Jon Hickman Ladenburg Thalmann	Ladenburg Thalmann	Strong Buy Maintains $7.25 → $8.25	Strong Buy	Maintains	$7.25 → $8.25	+47.06%	May 9, 2025
Jacob Stephan Lake Street	Lake Street	Strong Buy Maintains $6 → $7	Strong Buy	Maintains	$6 → $7	+24.78%	May 9, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

76.65M

Increased by 31.28%

from 58.38M

Revenue Next Year

91.48M

Increased by 19.36%

from 76.65M

EPS This Year

0.12

Increased by 78.50%

from 0.07

EPS Next Year

0.19

Increased by 51.02%

from 0.12

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	24.12M	29.46M	38.03M	47.27M	58.38M	76.65M	91.48M	116.08M
Revenue Growth	-30.42%	22.16%	29.08%	24.30%	23.50%	31.28%	19.36%	26.89%
EPS	-0.19	-0.05	0.02	0.12	0.07	0.12	0.19	0.22
EPS Growth	-	-	-	507.71%	-41.67%	78.50%	51.02%	18.92%
Forward PE	-	-	-	-	-	44.90	29.73	25.00
No. Analysts	-	-	-	-	-	6	6	3

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027
High	81.2M	105.0M	119.5M
Avg	76.6M	91.5M	116.1M
Low	70.6M	78.5M	111.5M

Revenue Growth

Revenue Growth	2025	2026	2027
High	39.1%	37.0%	30.6%
Avg	31.3%	19.4%	26.9%
Low	21.0%	2.5%	21.9%

EPS Forecast

EPS	2025	2026	2027
High	0.14	0.25	0.23
Avg	0.12	0.19	0.22
Low	0.12	0.16	0.22

EPS Growth

EPS Growth	2025	2026	2027
High	95.0%	101.7%	22.4%
Avg	78.5%	51.0%	18.9%
Low	68.0%	25.5%	14.3%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.